LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Cerus Corp

Cerus Corp

Closed

Sector Healthcare

2.02 -2.42

Buy Sell

Overview

Share price change

24h

Current

Min

2.02

Max

2.03

Key metrics
By Trading Economics
Sales	7M 47M
EPS	-0.01
Employees	288

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+172.28 upside

Dividends
By Dow Jones
Next Earnings	31 Oct 2024

Market Stats
By TradingEconomics
Market Cap	339M
Previous open	4.44
Previous close	2.02

News Sentiment

By Acuity

50%

114 / 365 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 2.355 Support & Resistance

Cerus Corp Chart

Related News

19 Mar 2024, 16:12 UTC

Major Market Movers

Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial

Peer Comparison

Price change

Cerus Corp Forecast

Price Target

By TipRanks

172.28% upside

12 Months Forecast

Average 5.5 USD 172.28%

High 6 USD

Low 5 USD

Based on 3 Wall Street analysts offering 12 month price targets forCerus Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

3 ratings

Buy

Hold

Sell

Based on 3 analysts giving stock ratings to Cerus Corp - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 2.355Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

114 / 365 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Cerus Corp

Cerus Corporation is a biomedical products company. It is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.